Lite Strategy, Inc.
0JW9.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$43.21M
Close$
$0.17
86.6% downside
Current Fair Value
86.6% downsideOvervalued by 86.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $43.21 Million |
|---|---|
| Enterprise Value | $35.67 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.06 |
| Beta | 0.04 |
| Outstanding Shares | 34,617,171 |
Return
| Return on Equity | -107.01% |
|---|---|
| Return on Assets | -105.24% |
| Return on Invested Capital | -102.04% |
Valuation & Multiples
| P/E Ratio | -0.14 |
|---|---|
| PEG | -0.02 |
| Price to Sales | - |
| Price to Book Ratio | 1.23 |
| Enterprise Value to Revenue | 29.82 |
| Enterprise Value to EBIT | -0.62 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 29, 2026
EPS Estimate
$-3.12
Average shareholder expectationRevenue Estimate
$5.41 M
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-3.12
Average shareholder expectationRevenue Estimate
$5.41 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About MEI Pharma Inc
5 employees
CEO: Daniel Gold Lite Strategy, Inc. is a pharmaceutical company currently in the clinical development phase, primarily dedicated to creating novel treatments for various forms of cancer. Among its key initiatives, the company is advancing ME-344, an int...